Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden.
Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases earlier and more accurately than previously possible.
Decades of clinical immunoproteomics research resulted in the development of IMMray™, our core technology platform based on antibody microarray analysis.
IMMray™ is dedicated to the early diagnosis of cancer, to predicting disease progression and to monitoring the therapeutic responsiveness of cancers. The platform technology can also be used for biomarker discovery through Immunovia’s discovery tool for proteome scanning IMMray™ PS (Proteome Survey). Immunovia’s technology is designed not only for cancer but also for autoimmune diseases. It is superior to conventional proteomic technologies that suffer from low throughput and impaired resolution and sensitivity.
The first test based on Immunovia’s platform, IMMray™ PanCan-d, is now under commercialization with several clinical evidence studies in the planning phase and also ongoing. IMMray™ PanCan-d is the only blood-based test available for early detection of pancreatic cancer in stage I and stage II when the cancer is still resectable. Diagnosing patients in stage I and stage II could increase the overall 5-year survival rate from 3-4% to approx. 59%1.
Immunovia’s solution combines a single-chain fragment variable (scFv) antibody library in an array-based set-up, antibody biomarker signatures and an advanced, in-house developed clinical algorithm and software for interpreting the data. The company has its own antibody library, antibody production and purification as well as its own chip/array production. Our clinical laboratory services are now undergoing validation for ISO accreditation.
Antibody microarray full system solution - including reference laboratory read-outs (from in-house antibody development - scFV - through microarray developments, microarray scanning, biomarker quantification, establishment of predictive biomarker profiles based on in-house developed biostatistics/software and cohort read-outs).
Immunovia applies front-edge bioinformatic workflows and tools for analyzing microarray data, including data handling, normalization, biomarker signature identification and classification. The microarray data generated is used to build Immunovia’s own predictive model based on biomarker signatures and the support vector machine (SVM) classification algorithm.
Biomarker signatures able to accurately classify/distinguish a disease state are identified through a stepwise biomarker/analyte selection process. One biomarker is excluded at a time in an iteration process adopting Immunovia’s in-house developed backward elimination approach. The backward elimination algorithm, based on SVM classification, generates the combination of biomarkers showing the highest classification power between healthy and disease states.
As part of the production unit, Immunovia’s in-house recombinant antibody production and purification platform provides high quality antibodies for microarray fabrication.
Recombinant antibodies are produced and purified in-house using robotic systems and high-throughput processes.
The source of renewable recombinant antibodies is crucial when to produce antibody-based microarray tests. Therefore, we use a specially designed library of recombinant antibodies, specifically designed at the molecular level, to ensure the availability of antibodies with optimal function of the chip.
Immunovia AB has not received any reviews.
Immunovia AB has not received any endorsements.